{Reference Type}: Journal Article
{Title}: Lymphocyte-Directed Immunomodulation Remits Thymoma-Associated Autoimmune Pneumonitis.
{Author}: Ferré EMN;Nichols-Vinueza DX;Rosen LB;Burbelo PD;Fennelly KP;Pechacek J;Goldstein DM;Agharahimi A;Saksena A;Kleiner DE;Demirdag YY;Rajan A;Schrump DS;Holland SM;Freeman AF;Lionakis MS;
{Journal}: J Clin Immunol
{Volume}: 44
{Issue}: 7
{Year}: 2024 Jul 1
{Factor}: 8.542
{DOI}: 10.1007/s10875-024-01760-3
{Abstract}: <B>BACKGROUND: </B>Thymoma presents with several autoimmune manifestations and is associated with secondary autoimmune regulator (AIRE) deficiency. Pneumonitis has recently been described as an autoimmune manifestation associated with thymoma presenting with similar clinical, radiographic, histological, and autoantibody features as seen in patients with inherited AIRE deficiency who suffer from Autoimmune PolyEndocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) syndrome.<BR><B>OBJECTIVE: </B>To treat two patients with biopsy-proven thymoma-associated pneumonitis with lymphocyte-directed immunomodulation.<BR><B>METHODS: </B>Two patients with thymoma were enrolled on IRB-approved protocols at the NIH Clinical Center. We performed history and physical examination; laboratory, radiographic, histologic and pulmonary function evaluations; and measurement of the lung-directed autoantibodies KCNRG and BPIFB1 prior to and at 1- and 6-months following initiation of lymphocyte-directed immunomodulation with azathioprine with or without rituximab.<BR><B>RESULTS: </B>Combination T- and B-lymphocyte-directed immunomodulation resulted in improvement of clinical, functional, and radiographic parameters at 6-month follow-up evaluations in both patients with sustained remission up to 12-36 months following treatment initiation.<BR><B>CONCLUSIONS: </B>Lymphocyte-directed immunomodulation remitted autoimmune pneumonitis in two patients with thymoma.